Karjalainen JM - Search Results

1

Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma.

Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ, Alhava EM, Kosma VM. Karjalainen JM, et al. Am J Pathol. 2000 Sep;157(3):957-65. doi: 10.1016/S0002-9440(10)64608-1. Am J Pathol. 2000. PMID: 10980134 Free PMC article.

2

Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma.

Karjalainen J, Eskelinen M, Kosma VM, Lipponen P, Tuominen L, Alhava E. Karjalainen J, et al. Anticancer Res. 1992 Sep-Oct;12(5):1507-11. Anticancer Res. 1992. PMID: 1444213

3

Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.

Karjalainen JM, Eskelinen MJ, Nordling S, Lipponen PK, Alhava EM, Kosma VM. Karjalainen JM, et al. Br J Cancer. 1998 Jun;77(11):1917-25. doi: 10.1038/bjc.1998.318. Br J Cancer. 1998. PMID: 9667668 Free PMC article.

4

Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma.

Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Karjalainen JM, et al. J Clin Oncol. 1998 Nov;16(11):3584-91. doi: 10.1200/JCO.1998.16.11.3584. J Clin Oncol. 1998. PMID: 9817279

5

p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.

Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinikainen M, Alhava EM, Kosma VM. Karjalainen JM, et al. Br J Cancer. 1999 Feb;79(5-6):895-902. doi: 10.1038/sj.bjc.6690143. Br J Cancer. 1999. PMID: 10070887 Free PMC article.

6

Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma.

Karjalainen JM, Kellokoski JK, Mannermaa AJ, Kujala HE, Moisio KI, Mitchell PJ, Eskelinen MJ, Alhava EM, Kosma VM. Karjalainen JM, et al. Br J Cancer. 2000 Jun;82(12):2015-21. doi: 10.1054/bjoc.2000.1145. Br J Cancer. 2000. PMID: 10864211 Free PMC article.

7

Transcription factors and other dysregulated proteins in melanoma prognosis.

Karjalainen JM. Karjalainen JM. Curr Oncol Rep. 2001 Jul;3(4):368-75. doi: 10.1007/s11912-001-0091-7. Curr Oncol Rep. 2001. PMID: 11389823 Review.

8

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers.

Mars N, Koskela JT, Ripatti P, Kiiskinen TTJ, Havulinna AS, Lindbohm JV, Ahola-Olli A, Kurki M, Karjalainen J, Palta P; FinnGen; Neale BM, Daly M, Salomaa V, Palotie A, Widén E, Ripatti S. Mars N, et al. Nat Med. 2020 Apr;26(4):549-557. doi: 10.1038/s41591-020-0800-0. Epub 2020 Apr 7. Nat Med. 2020. PMID: 32273609

9

The role of polygenic risk and susceptibility genes in breast cancer over the course of life.

Mars N, Widén E, Kerminen S, Meretoja T, Pirinen M, Della Briotta Parolo P, Palta P; FinnGen; Palotie A, Kaprio J, Joensuu H, Daly M, Ripatti S. Mars N, et al. Nat Commun. 2020 Dec 14;11(1):6383. doi: 10.1038/s41467-020-19966-5. Nat Commun. 2020. PMID: 33318493 Free PMC article.

10

Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.

Palomäki A; FinnGen Rheumatology Clinical Expert Group; Palotie A, Koskela J, Eklund KK, Pirinen M; FinnGen; Ripatti S, Laitinen T, Mars N. Palomäki A, et al. Ann Rheum Dis. 2021 Dec;80(12):1530-1536. doi: 10.1136/annrheumdis-2021-220698. Epub 2021 Aug 3. Ann Rheum Dis. 2021. PMID: 34344703 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters